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Tobacco glycoprotein (TGP)' is a brown, iron-containing  substance of mol wt 
ca.  18,000  isolated from saline extracts of flue cured tobacco leaves by ammo- 
nium sulfate fractionation,  chromatography on Sephadex G-25, and continuous 
flow, preparative electrophoresis on alkaline polyacrylamide gel. 12 of 31 volun- 
teers (6/15 smokers and 6/16 nonsmokers) exhibited immediate cutaneous hyper- 
sensitivity reactions  characterized  by wheal  and  flare  development  and  local 
itching when injected intracutaneously with this material.  Immunochemically 
similar  material  was  demonstrated  in,  and  isolated  from,  cigarette  smoke. 
Antigenically cross-reactive material was also demonstrated in eggplants, green 
peppers, potatoes, and tomatoes, which like tobacco, are members of the family 
Solanaceae  (1). 
The brown color,  molecular weight,  amino  acid analysis,  iron content,  and 
presence of carbohydrate moiety in TGP correspond to that of an iron-protein- 
chlorogenic acid-rutin complex in cured tobacco leaves first reported by Wright 
et al.  (2).  Since rutin is chemically similar to quercetin,  a  substance known to 
activate factor XII (3), we examined whether TGP isolated from cured Virginia 
Bright tobacco leaves or from cigarette smoke condensate was capable of activat- 
ing  factor  XII  in  human  blood plasma.  In  experiments  described  below we 
demonstrated  that  TGP  derived  from cured tobacco leaves or from  cigarette 
smoke condensate contained rutin or a rutin-like substance and activated factor 
XII in samples of human plasma resulting in the generation of clotting activity, 
fibrinolytic activity, and kinin activity. 
Materials  and  Methods 
Tobacco Leaves  and Cigarette  Smoke Condensate.  Cured tobacco leaves of Virginia Bright 
variety were supplied by the American Tobacco Co. and by the Phillip Morris Co.  through the 
courtesy of  Dr. Robert C. Hockett of  The Council for  Tobacco Research-U. S. A., Inc.,  New York. 
Cigarette smoke condensate, produced from University of  Kentucky 1RI cigarettes  smoked in a 
standard manner was, also  courtesy of  Dr. Hockett, kindly supplied by Dr. M. R. Guerin of  Oak 
Ridge National Laboratories, Oak Ridge, Tenn. 
Isolation  of TGP.  TGP  was isolated from these sources essentially  according to methods 
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previously described, except that Bio/Gel P-6 (Bio-Rad Laboratories, Richmond, Calif.) was used 
instead of Sephadex-25 (1).  TGP derived from cured tobacco leaves will be referred to as TGP-L. 
TGP derived from cigarette smoke condensate will be referred to as TGP-CSC.  Both TGP-L and 
TGP-CSC were present as a single band when electrophoresed on alkaline polyacrylamide gels, as 
described previously (1). 
Rabbit Antiserum to TGP.  Rabbit antibodies to TGP were prepared as described previously 
(1). 
Rutin-Bovine Serum Albumin Conjugate  and Preparation  of Rabbit Antiserum  Thereto.  200 
mg of rutin (Sigma Chemical Co.,  St.  Louis,  Mo.) was suspended in 2 ml of phosphate-buffered 
physiologic saline, pH 7.4  (PBS),  in  a  glass beaker and the pH brought to  11.2-11.5  with 1 N 
NaOH. This was placed in an ice bath and 0.5 g of CNBr dissolved in 2.5 ml of dimethylformamide 
was added dropwise, pH was maintained at 10.5-11.0 by addition of 5 N NaOH with stirring for 7-8 
min. 10 mg of crystalline bovine serum albumin (BSA) (Sigma Chemical Co.) was added and the 
mixture stirred at room temperature for 2 h and overnight at 4°C. The mixture was then dialyzed 
for 2  days  against three changes  of PBS and then concentrated by pressure dialysis using an 
Amicon PM-10 filter (Amicon Corp., Scientific Systems Div., Lexington, Mass.) and applied to a 
2.5 x 50 cm column of Bio/Gel P-6 equilibrated with PBS. The brown rutin-BSA conjugate emerged 
with the void volume; unconjugated rutin emerged later as a  second peak. Rutin-BSA was then 
dialyzed exhaustively against Pyrex distilled water and lyophilized. The yellow-brown powder 
was stored for use at -20°C. Three Dutch-belted rabbits were each inoculated intracutaneously in 
two sites with 200/~g of rutin-BSA in complete Freund's adjuvant. They were boostered 3 wk later 
and bled after 2 more weeks. The serum was collected from the clotted blood and stored at -70°C. 
Hemagglutination  Inhibition  Assays.  Washed  human  erythrocytes  of blood  group  O  were 
tanned and coated with TGP according to methods described by Herbert (4L  Rabbit antisera to 
TGP,  rabbit antisera to rutin-BSA, and pooled normal rabbit serum were heat inactivated and 
adsorbed with washed packed type O erythrocytes. Serum dilutions were prepared in Microtiter U- 
plates (Cooke Laboratory Products Div., Dynatech Laboratories Inc., Alexandria, Va.). The titer 
of anti-TGP antibodies ranged between 1:256  and 1:1,024.  Serum from two of the rabbits immu- 
nized with rutin-BSA agglutinated TGP-coated erythrocytes in titers of 1:512 and 1:1,024.  Pooled 
normal rabbit serum contained no antibodies to TGP. 
Hemagglutination inhibition assays were performed according to methods described by Kwa- 
pinski (5). The capacity of ellagic acid (K&K Laboratories Inc., Plainview, N. Y.), quercetin (Sigma 
Chemical  Co.),  rutin,  TGP-L,  TGP-CSC,  BSA,  or  PBS to  inhibit agglutination of TGP-coated 
erythrocytes by rabbit anti-TGP-L or by rabbit anti-rutin-BSA sera was measured. As a control for 
nonspecific  inhibition of agglutination,  tanned  human type  O  erythrocytes  were  coated  with 
human IgG purified by DEAE-cellulose  chromatography  and a  hemagglutination system  was 
constructed using heavy chain-specific rabbit antisera to human IgG (Behring Diagnostics, Ameri- 
can Hoechst Corp.,  Woodbury,  N.  Y.).  The capacity of human IgG, ellagic acid,  quercetin, rutin, 
TGP-L,  TGP-CSC,  or PBS to  inhibit agglutination of human IgG-coated erythrocytes by rabbit 
antiserum to IgG was measured.  The quantity of TGP-L or TGP-CSC in solution was determined 
by the Lowry et al. (6) modification of the technique of Folin and Ciocalteau, using a TGP standard 
as described previously (1). The quantity of BSA or IgG in solution was also determined by the Lowry 
method using a  BSA standard. The quantity of the other substances was determined gravimetri- 
cally. 
Human Plasma.  Normal human venous blood was obtained from laboratory personnel and 
anti-coagulated with sodium citrate (7).  Some donors had previously exhibited immediate cuta- 
neous hypersensitivity to TGP and some had not (1).  Platelets and other formed elements were 
removed by eentrifugation in plastic tubes at 4°C and plasma was pipetted with plastic pipette tips 
into plastic tubes and either placed in crushed ice before immediate use or stored at -70°C. Human 
plasma deficient in factor XII was obtained from George King Bio-Medical, Inc., Salem, N. H., and 
stored at  -70°C. 
Partial  Thromboplastin  Time.  A  fibrometer  (Baltimore Biological Laboratories,  Baltimore, 
Md.), plastic pipette tips, plastic tubes, and the following reagents were used: Celite (Filter Aid; 
Fisher Scientific Co.,  Pittsburgh,  Pa.)  in  PBS in  a  concentration of 5  mg/ml,  0.05M  CaCI~  in 
glyoxaline buffer  (7),  and rabbit brain cephalin (Sigma  Chemical  Co.)  in PBS.  In these experi- 
ments, 0.1 ml of plasma was pipetted in a  plastic reaction vessel and warmed at 37°C for 60 s. 0.1 
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solution  and  0.05  ml  of  CaCI2  solution  were  then  added  and  the  timer  and  probes  started.  The  timer 
stops  automatically when a clot  forms. The partial  thromboplastin  time (PTT) of  normal plasma 
activated  with  Celite  ranged between 75 and 100  s. When PBS was used instead  of  Celite  the  PTT 
was between 400 and 600 s depending on whether the plasma had been frozen  at -70°C or was 
fresh.  The following  substances,  dissolved  in  PBS, were tested  for  their  capacity  to  replace  Celite 
in this  assay:  TGP-L, TGP-CSC, ellagic  acid,  quercetin,  rutin,  rutin-BSA conjugate, BSA, rag- 
weed antigen E, beta lactoglobulin,  and PBS. All values represent  the mean of  duplicate  deter- 
minations. The coefficient  of  variation  in P'I'r  by this  technique was 6%. 
Euglobulin Clot Lysis Time.  The capacity of ellagic acid, quercetin, rutin, rutin-BSA, BSA, 
TGP-L, TGP-CSC,  and Celite to activate fibrinolysis was measured essentially according to the 
technique of Ogston et al.  (8). 
Citrated human plasma (0.5 ml) was incubated in plastic tubes with 0.9 ml of Celite suspension, 
PBS, or test substances for 60 rain at 37°C.  This mixture was then diluted with 11.5 ml of cold 0.01 
M sodium acetate buffer, pH 4.8, and euglobulin precipitated at 4°C for 30 rain. The tubes were 
centrifuged at 5,000 g  at 4°C,  the supernate decanted, and the precipitate dissolved in 0.5 ml of 
barbital saline buffer, pH 8.4 and transferred to 10 x 75 mm Pyrex tubes. 0.1 ml of bovine thrombin 
(Thrombin Topical; Parke, Davis & Co., Detroit, Mich.) in PBS at a concentration of 20 U/ml was 
then squirted in so that a  clot formed with bubbles. The tubes were then transferred to a  water 
bath at 37°C.  The clot lysis time was taken as the interval between the addition of thrombin and 
the lysis of the clot as indicated by the rise of trapped bubbles. All determinations were performed 
in duplicate. Values shown represent the mean of duplicate determinations. The concentrations of 
TGP-L  and  TGP-CSC  used  were  those  which  resulted  in  maximal  shortening  of the  partial 
thrornboplastin time. 
Kinin Generation.  0.2 ml of plasma was warmed for I  min at 30°C.  0.2 ml of 0.01 M disodium 
EDTA and 0.2 ml of the test substance at a  concentration in PBS known to shorten the partial 
thromboplastin time was then added and the mixture incubated at 37°C  for 3  rain. 0.2  ml of a 
solution of soybean trypsin inhibitor (Worthington Biochemical Corp., Freehold, N. J.) in PBS (4 
mg/ml) was then added. 0.4 ml of this mixture was then injected into a 10 ml De Jalon's buffer bath 
containing the uterine horn of a  150 g  Sprague-Dawley  rat in natural estrus.  Contraction was 
measured isotonically with a linear motion transducer, model ST-2, the transformer of which was 
supplied by an exciter demodulator (Phipps & Bird Inc., Richmond, Va.) and recorded on a Bausch 
and Lomb VOM-5  recorder,  as described  by  Harpel  (9).  Contractions were  compared to  those 
induced by standard dilutions of bradykinin triacetate (Sigma Chemical Co.) in De Jalon's buffer. 
The amount of kinin generated from plasma is expressed in terms of the bradykinin concentration 
necessary to induce comparable uterine contractions. Factor XII fragments were kindly provided 
by Dr. Peter C.  Harpel (9). 
Test for Endotoxin.  Solutions of ellagic acid,  quercetin,  rutin,  TGP-L,  TGP-CSC,  and PBS 
used as diluent were tested for bacterial endotoxin using the Limulus arnebocyte lysate test (10). 
Reagents for this assay were obtained from Microbiological Associates,  Bethesda,  Md.  Bacterial 
endotoxin was not demonstrable by this method in these solutions. 
Results 
Hemagglutination Inhibition Assay.  It can be seen in Table I that querce- 
tin,  rutin,  TGP-L,  and  TGP-CSC  can  inhibit agglutination of TGP-L-coated 
human type O erythrocytes by rabbit antiserum to rutin-BSA conjugate. This 
indicates that quercetin or rutin moieties are present in molecules of TGP-L and 
TGP-CSC and are arranged in such a way that they are immunologically active. 
The fact that TGP-CSC inhibits agglutination less well than TGP-L indicates 
that it contains less of  this moiety or that it has been altered during smoking. 
Ellagic acid, quercetin, rutin, TGP-L, and TGP-CSC inhibited agglutination 
of human type O erythrocytes coated with TGP-L by rabbit antiserum to TGP-L 
(Table II).  These observations indicate that moieties resembling ellagic acid, 
quercetin, or rutin are present in TGP and act as haptens to stimulate produc- 
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TABLE  I 
Hemagglutination  Inhibition Assay Comparing  TGP~L, TGP-CSC, Rutin, Quercetin, 
and Ellagic Acid, Using Rabbit Antibody to Rutin-BSA 
Minimum inhibiting an- 
Antigen  Rabbit serum*  Cell label  Agglutination  tigen concentration 
TGP-L  Anti-rutin-  TGP-L  -  125-250 ng/ml 
BSA 
TGP-CSC  Anti-rutin-  TGP-L  -  2.45-4.9  btg/ml 
BSA 
Rutin  Anti-rutin-  TGP-L  -  1 ~g/ml 
BSA 
Quercetin  Anti-rutin-  TGP-L  -  10 ~g/ml 
BSA 
Ellagic acid  Anti-rutin-  TGP-L  +  (No inhibition) 
BSA 
BSA  Anti-rutin-  TGP-L  +  (No inhibition) 
BSA 
PBS  Anti-rutin-  TGP-L  +  (No inhibition) 
BSA 
PBS  Anti-rutin-  Unlabeled  - 
BSA 
PBS  Normal  TGP-L  - 
PBS  Normal  Unlabeled  - 
* Serum was diluted 1:128. 
TABLE  II 
Hemagglutination  Inhibition Assay Comparing  TGP-L,  TGP-CSC, Rutin, Quercetin, 
and Ellagic Acid, Using Rabbit Antibody to TGP-L 
Minimum inhibiting an- 
Antigen  Rabbit serum*  Cell label  Agglutination  tigen concentration 
ug/ml 
TGP-L  Anti-TGP-L  TGP-L  -  5.9 
TGP-CSC  Anti-TGP-L  TGP-L  -  9.1 
Rutin  Anti-TGP-L  TGP-L  -  16 
Quercetin  Anti-TGP-L  TGP-L  -  16 
Ellagic acid  Anti-TGP°L  TGP-L  -  40 
BSA  Anti-TGP-L  TGP-L  +  (No inhibition) 
PBS  Anti-TGP-L  TGP-L  +  (No inhibition) 
PBS  Anti-TGP-L  Unlabeled  - 
PBS  Normal  TGP-L  - 
PBS  Normal  Unlabeled  - 
* Serum was diluted 1:360. 
on TGP  are  accessible  to macromolecules.  Neither  ellagic acid,  quercetin,  rutin, 
TGP-L,  nor  TGP-CSC  inhibited  agglutination  by  rabbit  antiserum  to  human 
IgG  of erythrocytes  coated  with  human  IgG,  although  human  IgG  in quantities 
as  low  as  100 ng/ml  inhibited  this  reaction. 
Effect of TGP-L and TGP-CSC on PTT.  The  effect of TGP-L  and  TGP-CSC 
on the  PTT  of normal  plasma  was  biphasic  (Table  III).  Certain  concentrations  of 
either  TGP-L  or TGP-CSC  shortened  the PTT  of normal  plasma,  whereas  higher 
concentrations  prolonged  the  PTT.  The  effect was  the  same  in plasma  irrespec- 
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TABLE  III 
Effect of Different Concentrations of TGP-L and TGP-CSC on 
PTT of Normal Plasma 
Concentration in reac- 
Substance  tion mixture  Clotting time 
#g  /ml  s 
TGP-L  400  685 
TGP-L  200  425 
TGP-L  100  350 
TGP-L  50  400 
TGP-L  25  450 
TGP-L  12.5  600 
Celite  1.66 mg/ml  83 
PBS  550 
TGP-CSC  250  729 
TGP-CSC  125  435 
TGP-CSC  63  375 
TGP-CSC  32  275 
TGP-CSC  16  435 
TGP-CSC  8  525 
TGP-CSC  3  560 
Celite  1.66 mg/ml  85 
PBS  570 
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TABLE  IV 
Effect of  Ellagic Acid, Quercetin, Rutin, TGP-L, TGP-CSC, and 
Rutin-BSA on PTT of  Normal Plasma and Plasma Deficient in 
Factor XII 
Clotting  Clotting time 
Concentration in re-  time  (factor XII-  Substance  action mixture  (normal  deficient 
plasma)  plasma) 
p~g/ml  s  s 
Ellagic acid  27  180  >1,200 
Quercetin  41  140.8  >1,200 
Rutin  41  173.3  > 1,200 
TGP-L  100  350  >1,200 
TGP-CSC  32  275  >1,200 
Rutin-BSA  83  280  >1,200 
BSA  83  600  >1,200 
Celite  1.66 mg/ml  83  >1,200 
PBS  550  >1,200 
TGP-L.  Concentrations  of TGP-L and TGP-CSC  which were optimal in shorten- 
ing the  PTT  of normal  plasma  did not shorten  the  PTT  of plasma  deficient in 
factor XII (Table IV). These observations indicate that TGP-L or TGP-CSC  can 
activate factor XII, presumably  because of quercetin or rutin  moieties. 
To test this hypothesis  we compared the effect of different concentrations  of 
rutin-BSA  conjugate  on  the  PTT  of normal  plasma.  The  effect was  similar to 
that produced by TGP-L or TGP-CSC  (Table V). High concentrations shortened 
the PTT of normal plasma.  Comparable  concentrations of BSA had  no effect on 
the  PTT.  Concentrations  of  rutin-BSA  which  shortened  the  PTT  of normal 462  ACTIVATION  OF  FACTOR  XII  BY  TOBACCO  GLYCOPROTEIN 
TABLE V 
Effect of Different Concentrations of Rutin-BSA and of BSA on 
PTT of Normal Plasma 
Concentration in reaction 
Substance  mixture  Clotting time 
~Lg  /  rn  l  s 
Rutin-BSA  330  >1,200 
Rutin-BSA  167  494 
Rutin-BSA  83  280 
Rutin-BSA  42  283 
Rutin-BSA  21  278 
Rutin-BSA  5.2  369 
Rutin-BSA  1.3  483 
Rutin-BSA  0,65  608 
Celite  1.66 mg/ml  93 
PBS  643 
BSA  330  600 
BSA  83  647.3 
BSA  21  635 
Celite  1.66 mg/ml  92.8 
PBS  621 
TABLE VI 
Effect of TGP-L or TGP-CSC on Thrombin Time of Normal 
Plasma 
Concentration in reac- 
Substance  Thrombin time 
tion mixture 
~g/ml  s 
TGP-L  400  22 
TGP-CSC  400  21 
PBS  21 
plasma had no effect on the PTT of plasma deficient in factor XII (Table IV). 
These  observations  indicate  that  the  attachment of rutin  or  quercetin-like 
moieties to protein converts normally inactive molecules to activators of factor 
XII. 
To see if the prolongation of PTT by high concentrations ofTGP-L, TGP-CSC, 
or rutin-BSA was due to a heparin-like effect, the effect of high concentrations of 
these substances on the thrombin time was measured in comparison to the PBS 
diluent control. These substances had no heparin-like effect on the thrombin 
time (Table VI). These studies suggest the capacity in high concentrations of 
TGP-L, TGP-CSC, or rutin-BSA to prolong the PTT of normal plasma is proba- 
bly due to complex formation with factor XII or other components of the first 
phase of the intrinsic blood coagulation system. 
In other experiments we examined the possibility of whether other purified 
allergens,  such as  antigen E  of ragweed or beta lactoglobulin of cow's milk, 
might also effect the PTT of normal plasma. These allergens had no effect. 
Effect  of TGP-L,  TGP-CSC,  and  Rutin-BSA  on  Activation  of Fibrinoly- 
sis.  Activation of factor XII by Celite, kaolin, or ellagic acid is known to result 
in activation of  the fibrinolytic system of normal plasma (8, 11, 12). Therefore, if CARL  G.  BECKER  AND  THEODORE  DUBIN 
TABLE VII 
Effect of TGP-L,  TGP-CSC,  Rutin, and Rutin-BSA on the 
Generation of Fibrinolytic Activity from Normal Plasma and 
from Factor XII-Deficient Plasma 
Final concentration 
Substance  in reaction mixture 
Clot lysis time 
Normal  Factor XII-de- 
plasma  ficient plasma 
gg /rnl  s  h 
TGP-L  100  345  >6 
TGP-CSC  32  375  >6 
Rutin  41  360  >6 
Rutin-BSA  83  390  >6 
BSA  83  840  >6 
Celite  1.66 mg/ml  315  >6 
PBS  870  >6 
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TGP-L, TGP-CSC, or rutin-BSA shortened the PTT by activating factor XII as 
these  data  suggest,  then  activation  of the  fibrinolytic  system  should  also be 
demonstrable in normal plasma treated with these substances.  Concentrations 
of TGP-L, TGP-CSC,  rutin,  or rutin-BSA that shorten PTT of normal plasma, 
like Celite, also shorten the lysis time of euglobulin clots (Table VII). The lysis 
time was not shortened by BSA or PBS diluent, nor was the euglobulin clot lysis 
time of factor XII-deficient plasma shortened by these substances.  These data 
provide further evidence that TGP-L or TGP-CSC activate factor XII because of 
quercetin or rutin-like  moieties. 
Generation of Kinin by TGP-L, TGP-CSC, Rutin, and Rutin-BSA.  In addi- 
tion  to  activating  the  intrinsic  blood coagulation  system and  the  fibrinolytic 
pathway of normal  plasma,  activation of factor XII is known to result  in the 
generation of bradykinin  (12,  13). 
Treatment of normal plasma with concentrations of TGP-L, TGP-CSC, rutin, 
or rutin-BSA conjugate, that resulted in shortening of PTT and euglobulin clot 
lysis  time  also  resulted  in  generation  of kinin  activity  as  measured  by the 
capacity of plasma to stimulate  contraction of the isolated uterine horn of the 
estrus rat (Table VIII). Treatment of normal plasma with ellagic acid, a known 
activator of factor XII, also resulted in generation of kinin activity. Neither BSA 
nor  PBS  diluent  initiated  kinin  generation  in  normal  plasma.  None  of the 
activator substances initiated  kinin  generation  in factor XII-deficient plasma. 
When factor XII fragments were added to factor XII-deficient plasma kinin was 
generated, indicating that with the exception of factor XII, the kinin generation 
system was otherwise intact. 
Discussion 
Glycoprotein isolated from flue cured Virginia Bright tobacco leaves (TGP-L) 
and  from  cigarette  smoke  condensate  (TGP-CSC)  (a)  shortened  the  PTT  of 
normal plasma;  (b) activated the fibrinolytic system of normal plasma; and (c) 
activated the generation  of kinin from normal  plasma.  These effects were not 
demonstrable in plasma from a patient deficient in factor XII (Hageman factor). 464  ACTIVATION OF  FACTOR XII  BY  TOBACCO GLYCOPROTEIN 
TABLE VIII 
The Generation of  Kinin Activity by Ellagic Acid, Rutin, TGP-L, 
TGP-CSC, and Rutin-BSA from Normal Plasma and from 
Factor XII-Deficient Plasma as Measured by Bioassay 
Substance 
Normal plasma (ng 
of bradykinin/0.1  ml 
of plasma) 
Factor XII-deficient 
plasma (ng of bra- 
dykinin/0.1  ml of 
plasma) 
Ellagic acid  >20  0 
Rutin  5  0 
TGP-L  15  0 
TGP-CSC  5  0 
Rutin-BSA  >20  0 
BSA  0  0 
PBS  0  0 
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FIG.  1.  Comparison of structures of ellagic acid. quercetin,  and rutin. 
Activation of factor XII is known to result in acceleration of the PTT, activation 
of the  fibrinolytic system,  and the  generation  of bradykinin  (12).  Thus,  these 
data indicate that TGP-L and TGP-CSC are capable of activating factor XII in 
normal plasma.  Although  TGP may directly  activate factor XII, it  is possible 
that this is accomplished indirectly through activation of high molecular weight 
kininogen  (14). 
The capacity of TGP to activate factor XII is due, apparently, to the presence 
of rutin.  Rutin closely resembles quercetin  and partially resembles ellagic acid 
(Fig.  1).  Quercetin and ellagic acid both are known to activate factor XII (3). In 
experiments described here, rabbit antibodies to rutin-BSA conjugates agglutin- 
ated tanned human type O erythrocytes coated with TGP-L. This agglutination 
was inhibited with quercetin,  rutin,  TGP-L, or TGP-CSC, indicating that rutin CARL  G.  BECKER  AND  THEODORE  DUBIN  465 
TGP 
Activation  of  Hageman  Factor  IgE-mediated  release 
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FIG. 2.  Hypothesis  concerning  the  relationship  of  TGP to  the  pathogenesis  of  pulmonary 
and cardiovascular disease. 
was  not  only present  in  molecules  of TGP-L  or  TGP-CSC,  but  that  it  was 
immunologically reactive.  TGP-L  was  a  more  potent  inhibitor  (Table  I)  of 
agglutination than TGP-CSC, indicating a higher content of rutin per molecule 
or  differences  in  the  arrangement  of rutin  on  the  molecule,  possibly  as  a 
consequence of  the smoking process. In similar experiments, rabbit antibodies to 
TGP-L agglutinated human type O erythrocytes coated with TGP-L. Agglutina- 
tion was inhibitable with ellagic acid, quercetin, rutin, TGP-L, and TGP-CSC. 
This experiment provides further evidence for the presence of rutin, or material 
resembling rutin, in TGP and indicates that substances with this structure can 
act  as  haptens  in  stimulating antibody production to  TGP.  Our  study also 
demonstrates that attachment of rutin to an otherwise inert carrier molecule, 
such as BSA, can cause the carrier to become an activator of factor XII. 
The  question  arises  as  to  whether the  separate phenomena of capacity to 
activate factor XII and immunogenicity are related functionally. It is conceiv- 
able that structures capable of activating factor XII are especially potent immu- 
nogens. It is known that activated factor XII stimulates macrophages to spread 
(15) and that macrophages are important to T-cell-B-cell collaboration in anti- 
body production (16). The high incidence of immediate cutaneous hypersensitiv- 
ity to TGP-L may be a function of  these interrelationships acting in concert with 
antigenic ubiquity, since antigens cross-reactive with TGP have been identified 
in  extracts  of other  common Solanaceae  such  as  eggplants,  green  peppers, 
potatoes, and tomatoes. 
The fact that TGP can activate factor XII and is a potent allergen may be the 
basis of the relationship between cigarette smoking, pulmonary disease,  and 
cardiovascular disease  (17-21).  A  working  hypothesis  is  outlined  in  Fig.  2. 
Inhalation of cigarette smoke could result in the chronic activation of factor XII 
and the generation of mediators of  the inflammatory  response by TGP, resulting 
in destruction of pulmonary parenchyma. Immunologically mediated release of 
vasoactive amines in response to TGP may act synergistically with this mecha- 
nism in the progression of pulmonary disease  (1,  22). When inhaled the rela- 
tively small  size  of TGP  (ca.  18,000 daltons)  may permit  easy access  to  the 466  ACTIVATION  OF  FACTOR  XII  BY  TOBACCO  GLYCOPROTEIN 
circulating blood. Activation of factor XII by TGP and initiation of thrombosis or 
kinin  generation  could  result  in  increased  endothelial  permeability  or  focal 
vascular  injury.  These  changes  may  be  augmented  by  the  immunologically 
induced release of vasoactive amines in the cigarette smoker hypersensitive to 
TGP (1,  22). 
Summary 
A glycoprotein of mol wt ca. 18,000 daltons isolated from cured tobacco leaves 
(TGP-L) and from cigarette smoke condensate (TGP-CSC) activated factor XII 
in normal human plasma in vitro as measured by (a) shortening of the partial 
thromboplastin time, (b) shortening of the lysis time of euglobulin clots, and (c) 
generation  of kinin  activity.  These  effects were  not  demonstrable  in  plasma 
deficient in factor XII.  The capacity of TGP-L and TGP-CSC to activate factor 
XII  was  shown  to  depend  on  the  presence  of rutin,  a  substance  chemically 
similar to quercetin and ellagic acid, which are known activators of factor XII. 
Rutin  and  rutin  coupled  to  bovine  serum  albumin,  but  not  bovine  serum 
albumin alone,  were also demonstrated to activate factor XII.  The presence in 
cigarette  smoke  of material  that  is both  allergenic  and  capable of activating 
factor  XII  of the  intrinsic  pathway  of coagulation  may  be  important  to  the 
pathogenesis of cardiovascular and pulmonary disease associated with cigarette 
smoking. 
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